The Psychedelic Access and Research European Alliance (PAREA) has launched a policy paper in line with a recent meeting on medical psychedelics in the European Parliament.
Global investment firm Psych Capital has announced the completion of its 100% acquisition of life science company Short Wave Pharma.
For the first time since Australia rescheduled MDMA and psilocybin, a shipment of the compounds has been made to the country to be used under the...
Psychedelic therapy company Sunstone Therapies has announced the start of its first study investigating multiple doses of psilocybin in the treatment of major depression disorder (MDD)...
A study from the Centre for Psychedelic Research at Imperial College London has shown that extended DMT IV infusions are safe and well tolerated.
A report has revealed that the consumption of ayahuasca is increasing in several countries.
The University of Exeter, UK, has launched the world’s first post-graduate course on psychedelics.
A new initiative, the PsychedeliCare Initiative, will launch in 2024 to bring citizens together to educate about psychedelics, call for the reshaping of drug policy and...
Health Canada has given Filament Health authorisation to carry out a Phase 2 clinical trial investigating PEX010 – the company’s botanical psilocybin drug candidate – for...
MIND Foundation’s INSIGHT Conference took place from August 31 to September 3 in Berlin, exploring the latest frontiers in psychedelic medicines – from clinical developments to...